SCHEMBL13097030

SCHEMBL13097030

FCCc1cc(Br)ccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
SREBF2 Q12772 1/20 0.34
MAPT P10636 4/20 0.33
LMNA P02545 3/20 0.33
CYP3A4 P08684 2/20 0.33
TSHR P16473 1/20 0.33
RECQL P46063 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HRH1 P35367 2/20 0.32
LOXL2 Q9Y4K0 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31
PLAU P00749 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13097029 0.88 KDM4E (0.36) KDM4EALDH1A1SMN1; SMN2CCNCCDK8
SCHEMBL27939066 0.85 KDM4E (0.39) KDM4EALDH1A1SMN1; SMN2CCNCCDK8
SCHEMBL15526376 0.83 HRH1 (0.50) KDM4EALDH1A1SMN1; SMN2CCNCCDK8
SCHEMBL23235054 0.83
SCHEMBL31278153 0.83
SCHEMBL2170011 0.80 HRH1 (0.46) KDM4EALDH1A1SMN1; SMN2CCNCCDK8
SCHEMBL539420 0.79 KDM4E (0.53) KDM4EALDH1A1SMN1; SMN2SREBF2MAPT
SCHEMBL15526283 0.79 KDM4E (0.42) KDM4EALDH1A1SMN1; SMN2CCNCCDK8
Hydrochloric Acid SCHEMBL1872727 0.79 HRH1 (0.44) KDM4EALDH1A1SMN1; SMN2CCNCCDK8
SCHEMBL721684 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8497260-B2 2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient Industry-University Cooperation Foundation Sogang University (KR) 2013-07-30 US disclosed
US-20100261727-A1 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT Industry-University Cooperation Foundation Sogang University 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261727-A1 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT APP, PSEN1, PSEN2 KDM4E 2295/4885ALDH1A1 3155/4885SMN1; SMN2 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.